TUNITAS THERAPEUTICS, INC.

Biotech · Private

GE2, a genetically engineered human fusion protein combining gamma1 and epsilon Fc chains for allergic disease treatment

Grants
$1.0M
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
2 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma$1,000,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3097NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER——
3098ImmPORT Therapeutics Inc dba Antigen Discovery Inc——
3099ASSUAGE PHARMACEUTICALS, INC.——
3100TUNITAS THERAPEUTICS, INC.——
3101KL50 THERAPEUTICS, LLC——
3102Medical Guidance Systems LLC——
3103TRIANGLE THERAPEUTICS INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 5

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.